- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03081871
Mobile Cardiovascular Risk Service Trial (mCVRS)
Design and Testing of a Mobile Cardiovascular Risk Service With Patient Partners
Přehled studie
Postavení
Detailní popis
Cardiovascular disease (CVD) causes 2,200 deaths in Americans every day with one death every 39 seconds. There is evidence that these deaths can be prevented with better risk factor management, however, many risk factors remain uncontrolled. The Patient-Centered Medical Home (Medical Home) which includes self-management, personalized health records and team-based care, has been proposed as a strategy to reduce these gaps in care delivery. Several Cochrane reviews and meta-analyses have found evidence that adding pharmacists to the primary care team improves risk factor control and physician adherence to guidelines. Managed care organizations have found that a centralized cardiovascular risk service (CVRS) managed by pharmacists can reduce mortality. A gap in the literature is that it is not known whether a comprehensive CVRS model would be implemented in typical office practices in un-integrated settings. Simultaneously, systematic reviews of mobile health (mHealth) trials including disease management apps have found no trial that has incorporated communication with a pharmacist and this lack of evidence is a major gap in the mHealth literature.
The objective of this application is to develop and test a mobile app enabled, pharmacist managed CVRS for disseminating and implementing evidence-based guidelines in practice. In addition to developing the app with patients as design partners, the investigators will conduct a multi-center individually randomized study nested within an ongoing NIH trial in medical offices with large geographic, racial and ethnic diversity. The study team will randomize 100 patients from primary care offices to mHealth CVRS (mobile app + web site + pharmacist) or to CVRS only (web site + pharmacist) of whom 55 will be from racial/ethnic minorities. The central hypothesis is that the mHealth CVRS designed with patients as partners will be implemented and significantly improve patient engagement, leading to improved CVD guideline adherence using the Get with The Guidelines and Guideline Advantage metrics. The rationale for this proposed study is that a novel mHealth model that improves secondary prevention of CVD with pharmacist assistance will lead to broader adoption by health systems throughout the US.
The primary Aim is: to examine the feasibility of mHealth technology to disseminate evidence-based risk reduction guidelines in a prospective randomized controlled trial among diverse primary care offices. The investigators postulate that system engagement (primary hypothesis) and adherence to guidelines for secondary prevention of CVD (secondary hypothesis) will be significantly greater in patients randomized to the mHealth intervention compared to the control group.
This study is expected to produce the following outcomes: unique mobile app features that complement the standard CVRS, increased engagement with a CVRS and increased achievement of guideline-concordant therapy.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa
-
Sioux City, Iowa, Spojené státy, 51105
- Siouxland Community Health Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
INCLUSION CRITERIA:
- Patients age 55 and older;
- Owns and uses a smartphone;
Any ONE of the following guideline-related needs in the past 18 months:
- Most recent encounter LDL >= 100 mg/dl
- Most recent encounter BP > 140/90 mmHg (or > 150/90 for persons age 60+)
- Most recent encounter not taking recommended post-stroke medications
- Most recent encounter not taking recommended post-MI medications
- Diabetics with most recent encounter not on ACE inhibitor or ARB blocker
- Any patient with most recent A1c > 8.0%
- Diabetics with no urine microalbumin screening, past 18 months
EXCLUSION CRITERIA:
- Non-English speaking (app available only in English for this study)
- No encounter in the past 18 months (they may be receiving care elsewhere and guideline-related needs may not be reliably assessed) at the clinic itself
- Most recent systolic BP >200 or diastolic BP > 110 mm Hg
- Any history of significant hepatic disease, including cirrhosis, Hepatitis B or C infection, or laboratory abnormalities (serum ALT or AST > 3 times normal (either AST above 96 U/L or ALT above 99 U/L or total bilirubin > 2.0 mg/dl))
- History of hemorrhagic stroke
- Pulmonary hypertension
- Stage 4 or metastatic cancer
- Current nursing home residence or has plans to move to one within the next 12 months
- Has plans to transfer care from the current clinic within the next 6 months
- Inability to give informed consent or impaired cognitive function
- Currently pregnant (females only)
- Currently a prisoner
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Výzkum zdravotnických služeb
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Web and mobile app access
Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
|
CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients.
The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation.
The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
|
Aktivní komparátor: Web app only access
Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
|
CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients.
The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation.
The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Mean number of days on which a patient interacts with the cardiovascular risk service (using either mobile app or web-site)
Časové okno: 4 months post enrollment
|
Mean number of days on which a patient interacts with the cardiovascular risk service (using either mobile app or web-site)
|
4 months post enrollment
|
Mean number of contacts with a pharmacist
Časové okno: 4 months post enrollment
|
Mean number of contacts with a pharmacist
|
4 months post enrollment
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Guideline Adherence score calculated on the subset of guidelines amenable to intervention during the 4 month intervention
Časové okno: 4 months post enrollment
|
Guideline Adherence score calculated on the subset of guidelines amenable to intervention during the 4 month intervention
|
4 months post enrollment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Elizabeth Chrischilles, PhD, University of Iowa
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 201603819
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .